Sorrell v. IMS Health Inc.
The Court struck down a Vermont law that barred pharmacies from selling doctors' prescription records to data companies when those records would be used by drug makers to market brand-name drugs to physicians.
Because the law singled out marketing speech and pharmaceutical marketers for special burdens while letting almost everyone else use the same data freely, the Court treated it as a content- and speaker-based restriction on speech that could not survive heightened First Amendment scrutiny.
“Speech in aid of pharmaceutical marketing, however, is a form of expression protected by the Free Speech Clause of the First Amendment.”
The Court's starting premise that marketing speech receives First Amendment protection.
How it got here: A federal trial court upheld Vermont's law after a bench trial; the Second Circuit reversed, finding a First Amendment violation; Vermont appealed to the Supreme Court, which took the case to resolve a conflict with First Circuit rulings on similar laws.
The Case in Depth
What happened
Pharmaceutical companies use "detailing" — sales visits to doctors — often relying on records showing a doctor's past prescriptions to tailor pitches for brand-name drugs. Vermont passed a law letting pharmacies sell or use that prescriber-identifying information for many purposes, but not for drug marketing, unless the doctor consented. Data-mining firms and a manufacturers' association sued, arguing the restriction violated their free-speech rights.
The question before the Court
Could Vermont bar pharmacies from selling records showing which drugs individual doctors prescribe to drug companies for use in marketing?
Why it matters
Drug companies and the data-mining firms that supply them can keep using detailed prescriber records to target sales pitches to individual doctors. States that want to curb aggressive pharmaceutical marketing or protect physician privacy must design narrower, viewpoint-neutral rules rather than laws that single out one kind of speaker or message for restriction.
What changes now
This is a final merits decision, not a remand for further proceedings on the First Amendment question itself; the Second Circuit's judgment invalidating the law is affirmed. Vermont and other states with similar prescriber-data restrictions must reconsider or redesign such laws to be content- and speaker-neutral if they want to survive First Amendment review, and the ruling resolved a split among federal appeals courts over similar Maine and New Hampshire laws.
What this does not decide
The Court did not decide that all restrictions on the use of government-mandated records are unconstitutional, nor that privacy-protective laws can never survive First Amendment review. It left open that a more narrowly drawn, content-neutral law restricting sale or disclosure of prescriber data in limited circumstances might be upheld.
Concurrences and dissents
Dissent — Justice Breyer
“The far stricter, specially “heightened” First Amendment standards that the majority would apply to this instance of commercial regulation are out of place here.”Breyer's core objection that the majority applied too strict a standard to an economic regulation.
Justice Breyer argued the law should be reviewed under a deferential standard for economic regulation, not heightened First Amendment scrutiny, because it only incidentally affected speech tied to a traditional regulatory scheme governing pharmacies and drug marketing. He contended that even under the stricter commercial-speech test from Central Hudson, Vermont's law was constitutional because it caused only modest harm to speech while directly advancing substantial interests in controlling health costs, ensuring balanced information, and protecting physician privacy, with no better alternative available.
How the Court got there
The legal reasoning, step by step
- The Court first asked whether Vermont's law was content-based and speaker-based on its face, since that classification determines what level of judicial scrutiny applies. It found the law restricted the sale, disclosure, and use of prescriber data specifically when the recipient's purpose was marketing, and specifically burdened pharmaceutical manufacturers as speakers while letting many other users of the same data go unrestricted.
- Because the law targeted particular content (marketing messages) and particular speakers (drug manufacturers and detailers) while leaving the same information free for other speakers and purposes such as research or counter-marketing by the state, the Court concluded this amounted to viewpoint discrimination, not a neutral commercial regulation.
- The Court held that content- and speaker-based restrictions on speech, including commercial speech, must survive heightened judicial scrutiny — meaning the government must show the law directly advances a substantial interest and is narrowly drawn to serve that interest, not merely that the restriction is convenient.
- Applying that standard, the Court examined Vermont's two stated goals — protecting physician privacy and lowering health care costs by curbing brand-name drug marketing — and found neither justified the law's design, because the statute let prescriber data flow freely to nearly everyone except detailers.
- The Court rejected the privacy rationale because the law did not actually restrict the information's dissemination in a meaningful way, and rejected the cost-control rationale because a state may not silence persuasive but truthful speech merely because it fears that speech will be effective in swaying doctors' decisions.
- Having found no adequate justification for the law's targeted burden on protected commercial expression, the Court concluded the statute could not satisfy heightened scrutiny under the First Amendment.
Doctrinal impact
Cases affected by this decision
Distinguishes Los Angeles Police Dept. v. United Reporting Publishing Corp. (528 U.S. 32)
The Court said this case about facial challenges to access restrictions did not control because Vermont's law burdened respondents' own speech directly.